Serotonergic-1a activity and contingent negative variation

Biological Psychology

Volumn 52, Issue 3, 2000, Pages 259-265

  Hansenne, Michel ^a   Pitchot, William ^a   Pinto, Emmanuel ^a   Papart, Patrick ^a   Ansseau, Marc ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

5 HT(1A); CNV; Flesinoxan; Psychopharmacology; Serotonin

Indexed keywords

FLESINOXAN; PROLACTIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINGENT NEGATIVE VARIATION; DEPRESSION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEROTONINERGIC SYSTEM;

ADULT; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RECEPTORS, SEROTONIN; REINFORCEMENT (PSYCHOLOGY); SEROTONIN AGONISTS;

EID: 0034162595     PISSN: 03010511     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0511(99)00047-2     Document Type: Article

References (25)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Association, Washington, DC.
2. Andreasen N.J.C., Peters J.F., Knott J.R. CNVs in hyperactive children: effects of chemotherapy. Mc Callum W.C., Knott J.R. The Responsive Brain. 1976;178-182 Wright, London.
3. Asthon H., Rawlins M.D. Central nervous system depressant actions of clonidine and UK-14,304: partial dissociation of EEG and behavioral effects. Br. J. Clin. Pharmacol. 5:1978;135-140.
4. Ashton H., Millman J.E., Telford R., Thompson J.W. The effect of caffeine, nitrazepam and cigarette smoking in man. Electroencephalogr. Clin. Neurophysiol. 37:1974;59-71.
5. Baumgartner A., Graf K.J., Kurten I. Prolactin in patients with major depressive disorder and in healthy subjects. II. Longitudinal study of basal prolactin and post-TRH-stimulated prolactin levels. Biol. Psychiatry. 24:1988;268-285.
6. De Vry J. 5HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
7. Groenink L., Van der Gugten J., Compaan J.C., Maes R.A., Olivier B. Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioral responses to a flesinoxan challenge. Psychopharmacology. 13:1997;93-100.
8. Hansenne M., Pitchot W., Gonzalez Moreno A., Gonzalez Torrecilas J., Mirel J., Ansseau M. Psychophysiological correlates of suicidal behavior in depression. A preliminary study. Neuropsychobiology. 30:1994;1-3.
9. Hansenne M., Pitchot W., Gonzalez Moreno A., Urcelay Zaldua I., Ansseau M. Suicidal behavior in depressive disorder: an event-related potential study. Biol. Psychiatry. 40:1996;116-122.
10. Jenck F., Martin J.R., Moreau J.L. The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J. Psychopharmacol. 13:1999;166-170.
11. Luthringer R., Rinaudo G., Toussaint M., Bailey P., Muller G., Muzet A., Macher J. Electroencephalographic characterization on brain dopaminergic stimulation by apomorphine in healthy volunteers. Neuropsychobiology. 39:1999;49-56.
12. Marczynski T.J. Cholinergic mechanism determines the occurrence of `reward contingent positive variation' (RCPV) in cat. Brain Res. 28:1971;71-83.
13. Papart P., Ansseau M., Timsit-Berthier M. CNV in mood disorders. Ogura C., Koga Y., Shimokoshi M. Recent Advances in Event-Related Brain Potential Research. 1996;897-900 Elsevier, Amsterdam.
14. Papart P., Ansseau M., Timsit-Berthier M. Influence of diazepam on contingent negative variation. Hum. Psychopharmacol. Clin. Exp. 12:1997;95-98.
15. Pick L.H., Halperin J.M., Schwartz S.T., Newcorn J.H. A longitudinal study of neurobiological mechanisms in boys with attention-deficit hyperactivity disorder: preliminary findings. Biol. Psychiatry. 45:1999;371-373.
16. Pierson A., Partiot A., Ammar S., Dodin V., Loas G., Jouvent R., Renault B. ERP differences between anxious-impulsive and blunted-affect depressive inpatients. Ansseau M., von Frenckell R., Frank G. Biological Markers of Depression: State of the Art. 1991;121-129 Elsevier, Amsterdam.
17. Pitchot W., Ansseau M., Gonzalez Moreno A., Lembreghts M., Hansenne M., Wauthy J., Reel C., Jammaer R., Papart P., Sulon J., Legros J-J. The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior. Pharmacopsychiatry. 28:1995;91-92.
18. Rockstroh B., Elbert T., Lutzenberger W., Altenmüller E. Effects of the anticonvulsant benzodiazepine clonazepam on event-related brain potentials in humans. Electroencephalogr. Clin. Neurophysiol. 78:1991;142-149.
19. Rösler F., Manzey D., Sojka B., Stieglitz R.D. Delineation of pharmacological effects by means of endogenous event-related brain potentials: an exemplification with flupentixol. Neuropsychobiology. 13:1985;81-92.
20. Stoff D.M., Pasatiempo A.P., Yeung J.H., Bridger W.H., Rabinovich H. Test-retest reliability of the prolactin and cortisol responses to D, L-fenfluramine challenge in disruptive behavior disorders. Psychiatry Res. 42:1992;65-72.
21. Tecce J.J., 1991. Dopamine and VCN: Studies of Drugs, Disease and Nutrition. In: Brunia, C.H.M., Mulder, G., Verbaten, M.N. (Eds.), Event-Related Brain Research, EEG SUPPL. 42. Elsevier, Amsterdam, pp. 153-164.
22. Tecce J.J., Cole J.O. Amphetamine effects in man: paradoxical drowsiness and lowered electrical brain activity (CNV). Science. 185:1974;451-453.
23. Thompson J.W., Asthon H., Golding J.F., Marsch V.R., 1986. Pharmacology of event-related potentials in humans. In: McCallum, W.C., Zappoli, R., Denoth, F. (Eds.), Cerebral Psychophysiology: Study in Event-Related Potentials, EEG SUPPL. 38. Elsevier, Amsterdam, pp. 374-383.
24. Timsit-Berthier M., 1991. Contingent Negative Variation (CNV) in Psychopharmacology. In: Brunia, C.H.M., Mulder, G., Verbaten, M.N. (Eds.), Event-Related Brain Research, EEG SUPPL. 42. Elsevier, Amsterdam, pp. 142-152.
25. Werre P.F., Mattie H., Fortgens C., Berretty E.W., Sluiter W. Interaction between extraversion and drug-induced conditions as indicated by the contingent negative variation. Biol. Psychol. 39:1994;45-56.